| Title |
Tumor-induced CD14+HLA-DR−/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, December 2014
|
| DOI | 10.1007/s00262-014-1646-4 |
| Pubmed ID | |
| Authors |
Zhitao Wang, Lulu Zhang, Huiping Wang, Shudao Xiong, Yanli Li, Qianshan Tao, Weihua Xiao, Hui Qin, Yiping Wang, Zhimin Zhai |
| Abstract |
Myeloid-derived suppressor cells (MDSCs) are heterogeneous, immature, myeloid progenitor cells, which suppress immune responses against tumors. CD14(+)HLA-DR(-/low) monocytic MDSCs (M-MDSC) are increased in patients suffering from multiple myeloma (MM). However, the frequency and function of M-MDSCs with the relationship between the tumor development and outcome of therapy in MM remain unclear. In this study, we analyzed the changes in M-MDSCs in newly diagnosed, relapsed and remission MM patients. In addition, we also assessed the response of M-MDSCs in MM patients treated with a bortezomib-based therapy as well as the impact of bortezomib on the modulation of M-MDSCs in vitro. The levels of M-MDSCs in newly diagnosed and relapsed MM patients were significantly increased compared with those in remission MM patients and healthy donors. Moreover, the levels of M-MDSCs were shown to correlate with tumor progression. The decrease in M-MDSCs after proteasome inhibitory therapy suggested that M-MDSCs could be considered as an indicator for the efficacy of therapy. Finally, we found the plasma from newly diagnosed MM patients, and MM cells were able to induce the accumulation of M-MDSCs in vitro. These results indicated that M-MDSCs could be considered as a prognostic predictor and an important cell type contributing to immune suppressive microenvironment in MM patients. Treatments targeting for M-MDSCs may improve therapeutic outcomes for MM patients. |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Belgium | 1 | 2% |
| Unknown | 56 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 25% |
| Student > Bachelor | 8 | 14% |
| Researcher | 7 | 12% |
| Student > Doctoral Student | 5 | 9% |
| Other | 5 | 9% |
| Other | 7 | 12% |
| Unknown | 11 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 32% |
| Immunology and Microbiology | 11 | 19% |
| Biochemistry, Genetics and Molecular Biology | 6 | 11% |
| Agricultural and Biological Sciences | 3 | 5% |
| Nursing and Health Professions | 2 | 4% |
| Other | 3 | 5% |
| Unknown | 14 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2014.
All research outputs
#19,015,492
of 23,577,654 outputs
Outputs from Cancer Immunology, Immunotherapy
#2,478
of 2,948 outputs
Outputs of similar age
#259,682
of 356,286 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#18
of 24 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,948 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 356,286 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.